Chronic News and Research

RSS

Behavioral economics tested in new health law

The new health law contains "many opportunities to nudge people toward better health choices. … 'In healthcare, for years and years and years there's been an interest in changing provider and consumer behavior,'" says Stanford professor Alan Garber. "What's new is that money is flowing into research on behavioral economics, and the government is getting involved, Garber and others said.

10 May 2010

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Competitive Technologies, Inc. announced today that Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, will present results of his study evaluating the treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTT's Calmare® Pain Therapy Treatment.

10 May 2010

QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain

QRxPharma announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.

10 May 2010

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Harbor Biosciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released an update to its development program for Triolex to treat obesity-induced insulin resistance and type-2 diabetes mellitus (T2DM).

10 May 2010

Asthmatx announces first U.S. patient treated with BT delivered by Alair System

Asthmatx, Inc. reported today that doctors at Virginia Hospital Center in Arlington, Va., recently treated the first U.S. patient with bronchial thermoplasty (BT) delivered by the Alair® System, the first device-based asthma treatment approved by the U.S. Food and Drug Administration (FDA).

10 May 2010

CFMG to adopt eClinicalWorks EMR system

eClinicalWorks®, a market leader in ambulatory clinical systems, today announced that California Forensic Medical Group (CFMG), which provides health care to correctional facilities in 25 counties in the state, has selected eClinicalWorks electronic medical records (EMR) system. Using eClinicalWorks will allow the group to streamline operations and improve the quality of care provided through reporting capabilities and the ability to share data across the counties. This will help in the continuity of care for inmates.

10 May 2010

Mice express pain through facial expressions, says study

A new study by researchers from McGill University and the University of British Columbia shows that mice, like humans, express pain through facial expressions.

10 May 2010

FDA approves Cipher's CIP-TRAMADOL ER for chronic pain

Cipher Pharmaceuticals Inc. today announced the U.S. Food and Drug Administration has approved CIP-TRAMADOL ER, the Company's extended-release tramadol product, for the treatment of moderate to moderately severe chronic pain in adults.

10 May 2010

AngioDynamics introduces redesigned Centros self-centering chronic hemodialysis access catheter

AngioDynamics announced today it has achieved the national launch of the newly redesigned Centros self-centering, chronic hemodialysis access catheter.

10 May 2010

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Forest Laboratories, Inc. and Nycomed today announced that they will present data from six roflumilast posters during the American Thoracic Society (ATS) International Conference being held in New Orleans, LA, May 14 through May 19, 2010. Roflumilast is an investigational anti-inflammatory, oral medication for the treatment of Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations.

10 May 2010

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells (ADRCs) for the treatment of no-option chronic heart disease patients showed the following: the procedure was safe and feasible; it demonstrated a statistically significant improvement in maximum oxygen consumption and patients' aerobic capacity measured as metabolic equivalents

10 May 2010

Integrated NextGen platform to be implemented at Aunt Martha's Youth Service Center

NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc., and leading provider of healthcare information systems and connectivity solutions, today announced it has executed an agreement with Aunt Martha's Youth Service Center to deploy NextGen® EHR, NextGen® Practice Management and electronic dental records from Quality Systems.

10 May 2010

Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei

Sosei Group Corporation announce the commencement of the Phase III clinical programme by Novartis, with QVA149, a once-daily, dry powder bronchodilator for inhalation combining a fixed dose of the once-daily beta2-agonist QAB149 (indacaterol) and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide) for the treatment of chronic obstructive pulmonary disease (COPD). The start of Phase III triggers a $7.5m milestone payment to Sosei.

10 May 2010

Steroids can raise cardiovascular risks in post-transplant patients

Post-transplant patients who have been removed from a corticosteroid regimen have fewer cardiovascular events than those patients on steroids, increasing their graft survival rates and reducing early mortality, according to study results being presented this week by University of Cincinnati (UC) transplantation researchers.

10 May 2010

Majority of Iraq and Afghanistan veterans experience multi-symptom pain disorders

Dr. Gallagher further noted the VA's pain care challenge is magnified by a 90 percent injury survivor rate from these conflicts compared with only 40 percent in the Vietnam War. VA clinicians are now challenged to manage pain in blast survivors with one or several other consequences of blast, such as head injuries causing mild to severe TBI, physical disfigurement and social stigma, emotional trauma, and often post traumatic stress disorder (PTSD).

10 May 2010

Insulin can help reduce risk of type 2 diabetes

Recent decades have seen a huge increase in type 2 diabetes and cardiovascular disease. This is a result of people being less active and eating fattier diets, which can lead to obesity and, in turn, diabetes.

10 May 2010

Proposal for regular health check ups for the mentally ill

SANE Australia has revealed data that shows that nearly 90% of patients with mental illness also suffer from chronic ailments like diabetes, heart disease etc.

9 May 2010

GP practices to get funds to employ full time nurses

There are nearly 40 percent GP practices in Australia who do not employ the services of a trained nurse. Authorities believe that there are 441,000 unnecessary hospital admissions each year only because of inability of patients to manage their chronic diseases due to lack of knowledge, or their inability to get adequate follow up care.

9 May 2010

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.

7 May 2010

New report: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease

Claims about the health benefits of foods and nutritional supplements have proliferated in recent years, most of them based on studies measuring ingredients' effects on biomarkers as substitutes for actual clinical outcomes.

7 May 2010

Chronic News and Research

Behavioral economics tested in new health law

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Asthmatx announces first U.S. patient treated with BT delivered by Alair System

CFMG to adopt eClinicalWorks EMR system

Mice express pain through facial expressions, says study

FDA approves Cipher's CIP-TRAMADOL ER for chronic pain

AngioDynamics introduces redesigned Centros self-centering chronic hemodialysis access catheter

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

Integrated NextGen platform to be implemented at Aunt Martha's Youth Service Center

Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei

Steroids can raise cardiovascular risks in post-transplant patients

Majority of Iraq and Afghanistan veterans experience multi-symptom pain disorders

Insulin can help reduce risk of type 2 diabetes

Proposal for regular health check ups for the mentally ill

GP practices to get funds to employ full time nurses

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

New report: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News